What Mr. Schneiderman has created in SCRC is a sol

What Mr. Schneiderman has created in SCRC is a solid business model supported by multiple revenue streams. Unlike other penny stocks defined by the "hope" of one concept, product, or service, SCRC's base is multi-faceted and financially strong. When you look at SCRC's different revenue streams, each has it's merits, but right now the compounding pharmacy is the Revenue King. In March, $494K in revenues were reported. In April with additional sales reps being added, SCRC could end up generating close to $1M. Pediatric RapiMeds, the product that gained all of our initial interest a year ago still has huge revenue potential (Hong Kong & Canada) in the long term, but right now as Joe states the compounding pharmacy is the revenue driver and will be for the next several months, and yes, even years. A positive cash flow penny stock company generating $12M+ a year can only be defined as a company destined for greatness. There is so much concern over the SCRC bashers, but I say once Mr. Schneiderman eliminates that last note, combined with the monthly compounding pharmacy increasing revenues, the P/S will grow to new heights and there is nothing anyone can say that will impede or stop SCRC's success.

Celtics told me when I first invested in SCRC a year ago that Q1 & Q2 of 2014 will be the start of the rise to greatness. Although he openly admitted to missing some projections along the way, I believe he will be spot on with this one. This rocket has been on the launch pad with boosters ready to fire for several months. The launch is imminent and the explosive sound of SCRC soaring into space will be heard all around the business world and new investors will be lining up to buy this incredible stock. The time to get excited is NOW! Our patience will be rewarded beyond our expectations. GO SCRC!!!